N/A N=56 The Autonomic Nervous System and the Metabolic Syndrome
Obesity
Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=210 Study of CB-183,315 in Participants With Clostridium Difficile Infection
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment — 61; 58; 59 participants
N/A N=12 Trial of Aripiprazole in Trichotillomania
Trichotillomania
Primary: Mass General Hair Pulling Scale — -7.8 units on a scale
N/A N=4 Metabolomic Analysis of Hepatic Insulin Resistance
Type 2 Diabetes · Obesity
Primary: Insulin Sensitivity — 8 m value — p=<0.05
Phase 2 N=38 CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I
Spinal Muscular Atrophy Type I
Primary: Laboratory Safety Data
N/A N=80 Efficacy of Electroacupuncture (EA) for Women With Pure Stress Urinary Incontinence (SUI)
Stress Urinary Incontinence
Primary: Change From Baseline of Urine Leakage Measured by 1-hour Pad Test — 2.50; 0.05 g
Phase 3 N=363 Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Moderate or Severe Submental Fullness
Primary: Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response — 59.2; 65.3; 23.0 percentage of participants — p=<0.001
Phase 2 N=73 Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
Moderate or Severe Submental Fullness
Primary: Number of Participants With Adverse Events — 24; 13; 20; 14 participants
Phase 4 N=270 Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief
Ankle Sprain
Primary: Sum of Pain Intensity Difference (SPID)1-3 Days — 3.981; 3.264 Score on scale — p=0.0201
N/A N=80 Oral Irritation Study of Two Experimental Mouthrinses
Oral Manifestations
Primary: Percentage of Participants With an Abnormal Condition by Anatomical Site at Screening — 0; 0; 0; 0 Percentage of Participants
N/A N=105 Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia
Schizophrenia
Primary: Medication Adherence-pill Count — 80.8; 81.43; 57.3 percentage of medication taken
N/A N=151 Nuevo Amanecer: Promoting the Psychosocial Health of Latinas
Breast Neoplasms · Psychology, Social
Primary: Physical Well-being a Subcale of the Functional Assessment of Cancer Therapy-Breast Quality of Life Instrument (FACT-B) — 15.29; 16.76; 19.44; 18.44 units on a scale…
N/A N=12 Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: Gaps Days Between Prescription Refills for Dabigatran, Rivaroxaban, and Apixaban — 43; 51; 41; -5 days
Phase 1 N=14 Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants
Phase 2 N=69 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Diffuse Astrocytoma
Primary: Maximum Tolerated Dose (Phase I) — 15 mg